For patients with non-squamous NSCLC, molecular testing is recommended for genomic alterations in 11 genes (EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2) in addition to PD-L1 immunohistochemistry (IHC) using a broad next-generation sequencing (NGS) panel to capture oncogenic driver alterations for matched FDA-approved therapies or clinical trials (13). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.